Trial: Phase III, Open-label, Study of First-l…

Trial Details

Sponsor: AstraZeneca (industry)

Phase: 3

Start date: April 11, 2024

Planned enrollment: 675

Trial ID: NCT06357533

More trial details at ClinicalTrials.gov

Show Summary from Sponsor

Investigational Drug AI Analysis

Show for: Datopotamab deruxtecan (Dato-DXd, DS-1062)

Overview

Datopotamab deruxtecan (Dato-DXd; DS-1062; marketed as Datroway) is a TROP2-directed antibody–drug conjugate developed for solid tumors. It is no longer solely investigational: in the United States it is approved for selected patients with HR-positive/HER2-negative or triple-negative breast cancer and, under accelerated approval, previously treated EGFR-mutated non-small-cell lung cancer (NSCLC). Studies in other disease settings and treatment combinations remain ongoing. (fda.gov)

Mechanism of action

Dato-DXd comprises a humanized anti-TROP2 IgG1 antibody connected through a cleavable linker to DXd, a potent exatecan-derived topoisomerase-I inhibitor. After binding TROP2 and internalization, lysosomal processing releases DXd, causing DNA damage and apoptosis. Preclinical evidence also supports a bystander effect against neighboring cells and induction of features associated with immunogenic cell death. (pmc.ncbi.nlm.nih.gov)

Efficacy

Previously treated HR-positive/HER2-negative breast cancer: In the randomized phase III TROPION-Breast01 trial (732 patients), Dato-DXd improved progression-free survival versus investigator-selected chemotherapy (hazard ratio 0.63). Objective response rates were 36.4% versus 22.9%, with median response durations of 6.7 and 5.7 months, respectively. Overall-survival data were immature in the primary publication. (ascopubs.org)
Previously untreated advanced triple-negative breast cancer unsuitable for immunotherapy: In phase III TROPION-Breast02 (644 patients), median progression-free survival was 10.8 versus 5.6 months, median overall survival was 23.7 versus 18.7 months, and objective response rates were approximately 63–64% versus 29–30% for Dato-DXd and chemotherapy, respectively. (sciencedirect.com)
Previously treated advanced NSCLC: In phase III TROPION-Lung01, median progression-free survival was 4.4 versus 3.7 months with Dato-DXd and docetaxel, while overall survival did not differ significantly. Benefit was concentrated in the prespecified nonsquamous subgroup; outcomes did not favor Dato-DXd in squamous disease. (pubmed.ncbi.nlm.nih.gov)
Previously treated EGFR-mutated NSCLC: A pooled FDA analysis of 114 patients from TROPION-Lung05 and TROPION-Lung01 found an objective response rate of 45% and median response duration of 6.5 months, supporting accelerated approval. (fda.gov)

Safety

The characteristic toxicities include stomatitis/oral mucositis, nausea, ocular-surface reactions, alopecia and fatigue. Interstitial lung disease/pneumonitis is an important, potentially fatal risk requiring monitoring and treatment interruption when suspected. (pubmed.ncbi.nlm.nih.gov)

In TROPION-Breast01, grade 3 or higher treatment-related adverse events occurred in 20.8% with Dato-DXd versus 44.7% with chemotherapy; treatment-related oral mucositis/stomatitis occurred in 57.2%, ocular-surface events in 43.9%, and adjudicated drug-related pneumonitis in 3.9%, including one fatal event. In TROPION-Lung01, grade 3 or higher treatment-related events occurred in 25.6% versus 42.1% with docetaxel, while drug-related pneumonitis was more frequent with Dato-DXd (8.8% versus 4.1%). (ascopubs.org)

Show for: Rilvegostomig (AZD2936)

Overview

Rilvegostomig (AZD2936) is an investigational bispecific immune-checkpoint antibody being developed for solid tumors, most extensively studied in non-small-cell lung cancer (NSCLC). Clinical evidence remains preliminary and largely comes from the nonrandomized phase I/II ARTEMIDE-01 trial; randomized phase III NSCLC studies are ongoing. (pubmed.ncbi.nlm.nih.gov)

Mechanism of action

Rilvegostomig is a humanized IgG1 antibody that simultaneously targets PD-1 and TIGIT, inhibitory receptors found on T cells and natural killer cells. Dual blockade is intended to restore antitumor immune activity more effectively than inhibition of either pathway alone. Its Fc region contains three mutations designed to minimize Fc-mediated immune-effector activity. (ascopubs.org)

Efficacy

In checkpoint-inhibitor–experienced, PD-L1-positive advanced NSCLC, ARTEMIDE-01 established 750 mg intravenously every three weeks as the recommended phase II dose. Among patients treated at this dose, the objective response rate (ORR) was 5.6%, the six-month disease-control rate was 31.5%, and median progression-free survival (PFS) was 3.8 months. (pubmed.ncbi.nlm.nih.gov)

Updated results in 65 checkpoint-inhibitor–naïve patients receiving 750 mg every three weeks showed:

PD-L1 TPS 1–49%: ORR 29.0% (9/31), median duration of response 9.9 months, and median PFS 6.1 months.
PD-L1 TPS ≥50%: ORR 61.8% (21/34), including one complete response; median PFS was 12.3 months, while median duration of response was not yet reached.

These single-arm results cannot establish whether rilvegostomig is superior to currently available checkpoint inhibitors. (annalsofoncology.org)

Safety

In 83 checkpoint-inhibitor–experienced patients, 54.2% experienced a treatment-related adverse event, including 8.4% with grade 3 events; no dose-limiting toxicities were observed, and 2.4% discontinued because of treatment-related toxicity. Immune-mediated adverse events occurred in 18.1%. (pubmed.ncbi.nlm.nih.gov)

Among the 65 checkpoint-inhibitor–naïve patients in the later analysis, grade 3 treatment-related adverse events occurred in 12.3%, treatment-related discontinuations in 3.1%, and no grade 4 or 5 treatment-related events were reported. (annalsofoncology.org)

TrialFetch AI Analysis

Goal: Determine whether datopotamab deruxtecan (Dato-DXd) plus rilvegostomig or rilvegostomig alone improves first-line outcomes compared with pembrolizumab in advanced non-squamous NSCLC with high PD-L1 expression.

Patients: Adults with unresectable stage IIIB/IIIC or metastatic non-squamous NSCLC, PD-L1 expression in at least 50% of tumor cells, no actionable genomic alteration with an available first-line targeted therapy, measurable disease, and ECOG performance status 0–1. Prior systemic treatment for advanced disease is excluded, as are clinically significant interstitial lung disease or pneumonitis and certain uncontrolled illnesses.

Design: Global, randomized, open-label, three-arm phase III trial. The primary analyses assess progression-free and overall survival in the TROP2 biomarker-positive population.

Treatments: Participants receive intravenous Dato-DXd plus rilvegostomig, rilvegostomig alone, or pembrolizumab alone on day 1 of each 21-day cycle. Dato-DXd is a TROP2-directed antibody–drug conjugate that delivers a topoisomerase-I inhibitor payload to tumor cells. In previously treated non-squamous NSCLC, Dato-DXd improved progression-free survival versus docetaxel in a prespecified subgroup analysis; its efficacy in this first-line combination remains unproven. Rilvegostomig is an investigational bispecific antibody targeting PD-1 and TIGIT to enhance antitumor immune activity. In a single-arm study of checkpoint-inhibitor–naïve NSCLC with PD-L1 expression of at least 50%, its objective response rate was 61.8%; that result does not establish superiority to pembrolizumab. Pembrolizumab is an established PD-1–blocking first-line treatment for eligible patients with high-PD-L1 NSCLC.

Outcomes: Primary endpoints are blinded independent central review–assessed RECIST 1.1 progression-free survival and overall survival in TROP2 biomarker-positive participants. Secondary measures include progression-free and overall survival in the full analysis set, objective response, duration of response, second progression-free survival, patient-reported symptoms and functioning, pharmacokinetics, and immunogenicity. Adverse events and tolerability are also assessed.

Burden on patient: Moderate: all arms require an infusion-center visit every three weeks, with additional visits or procedures for imaging, laboratory monitoring, and patient-reported questionnaires. Tumor tissue is required for PD-L1, TROP2, and other biomarker testing; pharmacokinetic and immunogenicity assessments add blood sampling. The combination arm may require closer monitoring for Dato-DXd–associated oral, ocular, and pulmonary toxicity. The protocol information does not specify scan frequency or require a new biopsy, so the additional burden beyond usual cancer care cannot be quantified precisely.

Last updated: Sep 2026

Eligibility

Caution: ClinicalTrials.gov appears to have newer eligibility criteria than the version saved here. Review the current criteria in ClinicalTrials.gov.

Show Criteria

Inclusion Criteria:

* Histologically or cytologically documented non-squamous NSCLC.

* Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.

* Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.

* Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.

* Known tumour PD-L1 expression status defined as TC ≥ 50%

* At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline

* ECOG performance status of 0 or 1

* Adequate bone marrow reserve and organ function within 7 days before the first dose of study intervention

Exclusion Criteria:

* Prior systemic therapy for advanced/metastatic NSCLC.

* Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.

* History of another primary malignancy within 3 years

* Active or prior documented autoimmune or inflammatory disorders (with exceptions)

* Any evidence of severe or uncontrolled systemic diseases, including, but not limited to active bleeding diseases, active infection, active ILD/pneumonitis, cardiac disease.

* Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.

* History of non-infectious ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening

* Has significant pulmonary function compromise, as determined by the investigator

* Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.

* History of leptomeningeal carcinomatosis

* Known clinically significant corneal disease

* Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled

* History of active primary immunodeficiency

Sites (281)

Sort by distance to:

Research Site

Blacktown, 2148, Australia

No email / No phone

Status: Recruiting

Research Site

Birtinya, 4575, Australia

No email / No phone

Status: Recruiting

Research Site

Wodonga, 3690, Australia

No email / No phone

Status: Recruiting

Research Site

South Brisbane, QL 4101, Australia

No email / No phone

Status: Recruiting

Research Site

Gosford, 2250, Australia

No email / No phone

Status: Recruiting

Research Site

Clayton, 3168, Australia

No email / No phone

Status: Recruiting

Research Site

Wels, 4600, Austria

No email / No phone

Status: Recruiting

Research Site

Vienna, 1210, Austria

No email / No phone

Status: Recruiting

Research Site

Vienna, 1140, Austria

No email / No phone

Status: Recruiting

Research Site

Rankweil, 6830, Austria

No email / No phone

Status: Recruiting

Research Site

Linz, 4020, Austria

No email / No phone

Status: Recruiting

Research Site

Krems, 3500, Austria

No email / No phone

Status: Recruiting

Research Site

Innsbruck, 6020, Austria

No email / No phone

Status: Recruiting

Research Site

Liège, 4000, Belgium

No email / No phone

Status: Recruiting

Research Site

La Louvière, 7100, Belgium

No email / No phone

Status: Recruiting

Research Site

Hasselt, 3500, Belgium

No email / No phone

Status: Recruiting

Research Site

Bruges, 8000, Belgium

No email / No phone

Status: Recruiting

Research Site

Santa Maria, 97015-450, Brazil

No email / No phone

Status: Recruiting

Research Site

Barretos, 14784-400, Brazil

No email / No phone

Status: Recruiting

Research Site

Florianópolis, 88034-000, Brazil

No email / No phone

Status: Recruiting

Research Site

Ipatinga, 35162-189, Brazil

No email / No phone

Status: Recruiting

Research Site

Natal, 59075-740, Brazil

No email / No phone

Status: Recruiting

Research Site

Porto Alegre, 91350-200, Brazil

No email / No phone

Status: Recruiting

Research Site

Rio de Janeiro, 22211-230, Brazil

No email / No phone

Status: Recruiting

Research Site

São Paulo, 01221-020, Brazil

No email / No phone

Status: Recruiting

Research Site

Taubaté, 12030-200, Brazil

No email / No phone

Status: Recruiting

Research Site

Curitiba, 80730-150, Brazil

No email / No phone

Status: Recruiting

Research Site

Chicoutimi, G7H 5H6, Canada

No email / No phone

Status: Recruiting

Research Site

Vancouver, British Columbia, VSZ 4E6, Canada

No email / No phone

Status: Recruiting

Research Site

St. John's, Newfoundland and Labrador, A1B 3V6, Canada

No email / No phone

Status: Recruiting

Research Site

London, Ontario, N6A 4L6, Canada

No email / No phone

Status: Recruiting

Research Site

Oshawa, Ontario, L1G 2B9, Canada

No email / No phone

Status: Recruiting

Research Site

Lévis, Quebec, G6V 0B8, Canada

No email / No phone

Status: Recruiting

Research Site

Montreal, Quebec, H3T 1E2, Canada

No email / No phone

Status: Recruiting

Research Site

Montreal, Quebec, H3T 1M5, Canada

No email / No phone

Status: Recruiting

Research Site

Trois-Rivières, Quebec, G8Z 3R9, Canada

No email / No phone

Status: Recruiting

Research Site

Montreal, Quebec, H4J 1C5, Canada

No email / No phone

Status: Recruiting

Research Site

Rimouski, Quebec, G5L 5T1, Canada

No email / No phone

Status: Recruiting

Research Site

Saskatoon, Saskatchewan, S7N 4H4, Canada

No email / No phone

Status: Recruiting

Research Site

Beijing, 100142, China

No email / No phone

Status: Recruiting

Research Site

Beijing, 101149, China

No email / No phone

Status: Recruiting

Research Site

Changsha, 410013, China

No email / No phone

Status: Recruiting

Research Site

Chengdu, 610000, China

No email / No phone

Status: Recruiting

Research Site

Chengdu, 610041, China

No email / No phone

Status: Recruiting

Research Site

Chongqing, 400030, China

No email / No phone

Status: Recruiting

Research Site

Fuzhou, 350014, China

No email / No phone

Status: Recruiting

Research Site

Guangzhou, 510080, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310006, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310016, China

No email / No phone

Status: Recruiting

Research Site

Hangzhou, 310022, China

No email / No phone

Status: Recruiting

Research Site

Harbin, 150049, China

No email / No phone

Status: Recruiting

Research Site

Hefei, 230601, China

No email / No phone

Status: Recruiting

Research Site

Jinan, 250117, China

No email / No phone

Status: Recruiting

Research Site

Jining, 272011, China

No email / No phone

Status: Recruiting

Research Site

Kunming, 650118, China

No email / No phone

Status: Recruiting

Research Site

Lanzhou, 730000, China

No email / No phone

Status: Recruiting

Research Site

Linhai, 317000, China

No email / No phone

Status: Recruiting

Research Site

Linyi, 276001, China

No email / No phone

Status: Recruiting

Research Site

Nanjing, 210009, China

No email / No phone

Status: Recruiting

Research Site

Nanning, 530000, China

No email / No phone

Status: Recruiting

Research Site

Nanning, 530021, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200030, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200032, China

No email / No phone

Status: Recruiting

Research Site

Shanghai, 200433, China

No email / No phone

Status: Recruiting

Research Site

Shenyang, 110022, China

No email / No phone

Status: Recruiting

Research Site

Taiyuan, 030000, China

No email / No phone

Status: Recruiting

Research Site

Tianjin, 300060, China

No email / No phone

Status: Recruiting

Research Site

Wenzhou, 325000, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430000, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430010, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430022, China

No email / No phone

Status: Recruiting

Research Site

Wuhan, 430030, China

No email / No phone

Status: Recruiting

Research Site

Xi'an, 710061, China

No email / No phone

Status: Recruiting

Research Site

Yangzhou, 225001, China

No email / No phone

Status: Recruiting

Research Site

Zhengzhou, 450000, China

No email / No phone

Status: Recruiting

Research Site

Zhengzhou, 450008, China

No email / No phone

Status: Recruiting

Research Site

Hamburg, 22087, Germany

No email / No phone

Status: Recruiting

Research Site

Bonn, 53113, Germany

No email / No phone

Status: Recruiting

Research Site

Freiburg im Breisgau, 79106, Germany

No email / No phone

Status: Recruiting

Research Site

Gauting, 82131, Germany

No email / No phone

Status: Recruiting

Research Site

Georgsmarienhütte, 49124, Germany

No email / No phone

Status: Recruiting

Research Site

Gütersloh, 33332, Germany

No email / No phone

Status: Recruiting

Research Site

Hamburg, 20251, Germany

No email / No phone

Status: Recruiting

Research Site

Heidelberg, 69126, Germany

No email / No phone

Status: Recruiting

Research Site

Kempten, 87439, Germany

No email / No phone

Status: Recruiting

Research Site

Ludwigsburg, 71640, Germany

No email / No phone

Status: Recruiting

Research Site

Nuremberg, 90419, Germany

No email / No phone

Status: Recruiting

Research Site

Potsdam, 14467, Germany

No email / No phone

Status: Recruiting

Research Site

Ravensburg, 88212, Germany

No email / No phone

Status: Recruiting

Research Site

Győr, 9024, Hungary

No email / No phone

Status: Recruiting

Research Site

Kecskemét, 6000, Hungary

No email / No phone

Status: Recruiting

Research Site

Törökbálint, 2045, Hungary

No email / No phone

Status: Recruiting

Research Site

Szekszárd, 7100, Hungary

No email / No phone

Status: Recruiting

Research Site

Salgótarján, 3100, Hungary

No email / No phone

Status: Recruiting

Research Site

Budapest, 1121, Hungary

No email / No phone

Status: Recruiting

Research Site

Dwārka, 110075, India

No email / No phone

Status: Recruiting

Research Site

Jaipur, 302004, India

No email / No phone

Status: Recruiting

Research Site

Kolkata, 700099, India

No email / No phone

Status: Recruiting

Research Site

Thiruvananthapuram, 695011, India

No email / No phone

Status: Recruiting

Research Site

New Delhi, 11029, India

No email / No phone

Status: Recruiting

Research Site

New Delhi, 110085, India

No email / No phone

Status: Recruiting

Research Site

Nashik, 422011, India

No email / No phone

Status: Recruiting

Research Site

Nagpur, 440001, India

No email / No phone

Status: Recruiting

Research Site

Chennai, 600031, India

No email / No phone

Status: Recruiting

Research Site

Milan, 20162, Italy

No email / No phone

Status: Recruiting

Research Site

Genoa, 16132, Italy

No email / No phone

Status: Recruiting

Research Site

Bergamo, 24125, Italy

No email / No phone

Status: Recruiting

Research Site

Rozzano, 20089, Italy

No email / No phone

Status: Recruiting

Research Site

Roma, 00128, Italy

No email / No phone

Status: Recruiting

Research Site

Ravenna, 48100, Italy

No email / No phone

Status: Recruiting

Research Site

Pavia, 27100, Italy

No email / No phone

Status: Recruiting

Research Site

Padova, 35128, Italy

No email / No phone

Status: Recruiting

Research Site

Monza, 20052, Italy

No email / No phone

Status: Recruiting

Research Site

Milan, 20141, Italy

No email / No phone

Status: Recruiting

Research Site

Takaoka-shi, 933-8555, Japan

No email / No phone

Status: Recruiting

Research Site

Fukuoka, 814-0180, Japan

No email / No phone

Status: Recruiting

Research Site

Hidaka-shi, 350-1298, Japan

No email / No phone

Status: Recruiting

Research Site

Hirakata-shi, 573-1191, Japan

No email / No phone

Status: Recruiting

Research Site

Hirosaki-shi, 036-8563, Japan

No email / No phone

Status: Recruiting

Research Site

Hiroshima, 730-8518, Japan

No email / No phone

Status: Recruiting

Research Site

Kanazawa, 920-8641, Japan

No email / No phone

Status: Recruiting

Research Site

Kashiwa, 227-8577, Japan

No email / No phone

Status: Recruiting

Research Site

Kawasaki-shi, 216-8511, Japan

No email / No phone

Status: Recruiting

Research Site

Kumamoto, 860-8556, Japan

No email / No phone

Status: Recruiting

Research Site

Nagoya, 460-0001, Japan

No email / No phone

Status: Recruiting

Research Site

Niigata, 951-8566, Japan

No email / No phone

Status: Recruiting

Research Site

Okayama, 700-8558, Japan

No email / No phone

Status: Recruiting

Research Site

Osaka, 545-8586, Japan

No email / No phone

Status: Recruiting

Research Site

Osakasayama-shi, 589-8511, Japan

No email / No phone

Status: Recruiting

Research Site

Sagamihara-shi, 252-0375, Japan

No email / No phone

Status: Recruiting

Research Site

Sapporo, 003-0804, Japan

No email / No phone

Status: Recruiting

Research Site

Fukuoka, 812-8582, Japan

No email / No phone

Status: Recruiting

Research Site

Takatsuki-shi, 569-8686, Japan

No email / No phone

Status: Recruiting

Research Site

Tokushima, 770-8503, Japan

No email / No phone

Status: Recruiting

Research Site

Tokyo, 104-0045, Japan

No email / No phone

Status: Recruiting

Research Site

Utsunomiya, 320-0834, Japan

No email / No phone

Status: Recruiting

Research Site

Yokohama, 221-0855, Japan

No email / No phone

Status: Recruiting

Research Site

Bunkyō City, 113-8431, Japan

No email / No phone

Status: Recruiting

Research Site

Bunkyō City, 160-0023, Japan

No email / No phone

Status: Recruiting

Research Site

Warsaw, 02-781, Poland

No email / No phone

Status: Recruiting

Research Site

Warsaw, 01-138, Poland

No email / No phone

Status: Recruiting

Research Site

Przemyśl, 37-700, Poland

No email / No phone

Status: Recruiting

Research Site

Poznan, 60-569, Poland

No email / No phone

Status: Recruiting

Research Site

Olsztyn, 10-357, Poland

No email / No phone

Status: Recruiting

Research Site

San Juan, 00909, Puerto Rico

No email / No phone

Status: Recruiting

Research Site

Suwon, 16247, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 03722, South Korea

No email / No phone

Status: Recruiting

Research Site

Seoul, 03080, South Korea

No email / No phone

Status: Recruiting

Research Site

Seongnam-si, 13496, South Korea

No email / No phone

Status: Recruiting

Research Site

Incheon, 21565, South Korea

No email / No phone

Status: Recruiting

Research Site

Changwon, 51353, South Korea

No email / No phone

Status: Recruiting

Research Site

Suwon, 16499, South Korea

No email / No phone

Status: Recruiting

Research Site

Reus,Tarragona, 43204, Spain

No email / No phone

Status: Recruiting

Research Site

Barcelona, 08036, Spain

No email / No phone

Status: Recruiting

Research Site

Barcelona, 08003, Spain

No email / No phone

Status: Recruiting

Research Site

Alicante, 03010, Spain

No email / No phone

Status: Recruiting

Research Site

Jerez de la Frontera, 11407, Spain

No email / No phone

Status: Recruiting

Research Site

Taichung, 40705, Taiwan

No email / No phone

Status: Recruiting

Research Site

Kaohsiung City, 80756, Taiwan

No email / No phone

Status: Recruiting

Research Site

New Taipei City, 220, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taichung, 40447, Taiwan

No email / No phone

Status: Recruiting

Research Site

Tainan, 704, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 0116, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 10002, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, 112, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taipei, TAIWAN, Taiwan

No email / No phone

Status: Recruiting

Research Site

Taoyuan District, 333, Taiwan

No email / No phone

Status: Recruiting

Research Site

Bangkok, 10400, Thailand

No email / No phone

Status: Recruiting

Research Site

Mueang, 32000, Thailand

No email / No phone

Status: Recruiting

Research Site

Mueang, 20000, Thailand

No email / No phone

Status: Recruiting

Research Site

Muang, 22000, Thailand

No email / No phone

Status: Recruiting

Research Site

Hat Yai, 90110, Thailand

No email / No phone

Status: Recruiting

Research Site

Ankara, 6200, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Ankara, 06560, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Adapazarı, 54100, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Istanbul, 34890, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Istanbul, 34030, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Diyarbakır, 21280, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

Antalya, 07070, Turkey (Türkiye)

No email / No phone

Status: Recruiting

Research Site

London, SW10 9NH, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Truro, TR1 3LJ, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Preston, PR2 9HT, United Kingdom

No email / No phone

Status: Recruiting

Research Site

London, SW17 0QT, United Kingdom

No email / No phone

Status: Recruiting

Research Site

Anchorage, Alaska, 99508, United States

No email / No phone

Status: Recruiting

Research Site

Tucson, Arizona, 85719, United States

No email / No phone

Status: Recruiting

Research Site

Little Rock, Arkansas, 72205, United States

No email / No phone

Status: Recruiting

Research Site

Springdale, Arkansas, 72762, United States

No email / No phone

Status: Recruiting

Research Site

Fountain Valley, California, 92708, United States

No email / No phone

Status: Recruiting

Research Site

Anaheim, California, 92801, United States

No email / No phone

Status: Recruiting

Research Site

Beverly Hills, California, 90211, United States

No email / No phone

Status: Recruiting

Research Site

Clermont, Florida, 34711, United States

No email / No phone

Status: Recruiting

Research Site

Gainesville, Florida, 32608, United States

No email / No phone

Status: Recruiting

Research Site

Miami Beach, Florida, 33140, United States

No email / No phone

Status: Recruiting

Research Site

Orange City, Florida, 32763, United States

No email / No phone

Status: Recruiting

Research Site

West Palm Beach, Florida, 33401, United States

No email / No phone

Status: Recruiting

Research Site

Atlanta, Georgia, 30322, United States

No email / No phone

Status: Recruiting

Research Site

Atlanta, Georgia, 30318, United States

No email / No phone

Status: Recruiting

Research Site

Hinsdale, Illinois, 60521, United States

No email / No phone

Status: Recruiting

Research Site

Noblesville, Indiana, 46062, United States

No email / No phone

Status: Recruiting

Research Site

Annapolis, Maryland, 21401, United States

No email / No phone

Status: Recruiting

Research Site

Boston, Massachusetts, 02215, United States

No email / No phone

Status: Recruiting

Research Site

Boston, Massachusetts, 02114, United States

No email / No phone

Status: Recruiting

Research Site

Dearborn, Michigan, 48126, United States

No email / No phone

Status: Recruiting

Research Site

Farmington Hills, Michigan, 48334, United States

No email / No phone

Status: Recruiting

Research Site

Grand Rapids, Michigan, 49503, United States

No email / No phone

Status: Recruiting

Research Site

Hattiesburg, Mississippi, 39401, United States

No email / No phone

Status: Recruiting

Research Site

Kansas City, Missouri, 64132, United States

No email / No phone

Status: Recruiting

Research Site

Grand Island, Nebraska, 68803, United States

No email / No phone

Status: Recruiting

Research Site

Omaha, Nebraska, 68130, United States

No email / No phone

Status: Recruiting

Research Site

Las Vegas, Nevada, 89102, United States

No email / No phone

Status: Recruiting

Research Site

Stony Brook, New York, 11794, United States

No email / No phone

Status: Recruiting

Research Site

Salisbury, North Carolina, 28144, United States

No email / No phone

Status: Recruiting

Research Site

Maumee, Ohio, 43537, United States

No email / No phone

Status: Recruiting

Research Site

Cincinnati, Ohio, 45219, United States

No email / No phone

Status: Recruiting

Research Site

Toledo, Ohio, 43623, United States

No email / No phone

Status: Recruiting

Research Site

Greenville, South Carolina, 29607, United States

No email / No phone

Status: Recruiting

Research Site

Sioux Falls, South Dakota, 57105, United States

No email / No phone

Status: Recruiting

Research Site

Kingwood, Texas, 77339, United States

No email / No phone

Status: Recruiting

Research Site

Odessa, Texas, 79761, United States

No email / No phone

Status: Recruiting

Research Site

Fort Worth, Texas, 76104, United States

No email / No phone

Status: Recruiting

Research Site

Houston, Texas, 77030, United States

No email / No phone

Status: Recruiting

Research Site

Richmond, Virginia, 23230, United States

No email / No phone

Status: Recruiting

Research Site

Leesburg, Virginia, 20176, United States

No email / No phone

Status: Recruiting

Research Site

Fort Belvoir, Virginia, 22060, United States

No email / No phone

Status: Recruiting

Research Site

Tacoma, Washington, 98405, United States

No email / No phone

Status: Recruiting

Research Site

Vancouver, Washington, 98684, United States

No email / No phone

Status: Recruiting

Research Site

Wenatchee, Washington, 98801, United States

No email / No phone

Status: Recruiting

Research Site

Appleton, Wisconsin, 54911, United States

No email / No phone

Status: Recruiting

Research Site

Vĩnh Yên, 280000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Ho Chi Minh City, 700000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Hà Nội, 100000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Hanoi, 100000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Da Nang, 550000, Vietnam

No email / No phone

Status: Recruiting

Research Site

Changchun, 130000, China

No email / No phone

Status: Not yet recruiting

Research Site

Berlin, 10249, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Essen, 45136, Germany

No email / No phone

Status: Not yet recruiting

Research Site

München, 81925, Germany

No email / No phone

Status: Not yet recruiting

Research Site

Székesfehérvár, 8000, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Gyöngyös - Mátraháza, 3200, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Gyula, 5700, Hungary

No email / No phone

Status: Not yet recruiting

Research Site

Surat, 395002, India

No email / No phone

Status: Not yet recruiting

Research Site

Matsusaka-shi, 515-8544, Japan

No email / No phone

Status: Not yet recruiting

Research Site

Barcelona, 08041, Spain

No email / No phone

Status: Not yet recruiting

Research Site

Newport Beach, California, 92663, United States

No email / No phone

Status: Not yet recruiting

Research Site

Orlando, Florida, 32806, United States

No email / No phone

Status: Not yet recruiting

Research Site

Atlanta, Georgia, 30303, United States

No email / No phone

Status: Not yet recruiting

Research Site

Paducah, Kentucky, 42003, United States

No email / No phone

Status: Not yet recruiting

Research Site

Greenville, North Carolina, 27834, United States

No email / No phone

Status: Not yet recruiting

Research Site

Midlothian, Virginia, 23114, United States

No email / No phone

Status: Not yet recruiting

Research Site

Ho Chi Minh City, 700000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Hanoi, 100000, Vietnam

No email / No phone

Status: Not yet recruiting

Research Site

Melbourne, 3000, Australia

No email / No phone

Status: Withdrawn

Research Site

Anderlecht, 1070, Belgium

No email / No phone

Status: Withdrawn

Research Site

Winnipeg, Manitoba, R3E 0V9, Canada

No email / No phone

Status: Withdrawn

Research Site

Newmarket, Ontario, L3Y 2P9, Canada

No email / No phone

Status: Withdrawn

Research Site

Toronto, Ontario, M4N 3M5, Canada

No email / No phone

Status: Withdrawn

Research Site

Hefei, 230031, China

No email / No phone

Status: Withdrawn

Research Site

Düsseldorf, 40489, Germany

No email / No phone

Status: Withdrawn

Research Site

Gera, 07548, Germany

No email / No phone

Status: Withdrawn

Research Site

Gyöngyös, 3200, Hungary

No email / No phone

Status: Withdrawn

Research Site

Marg Jaipur, 302004, India

No email / No phone

Status: Withdrawn

Research Site

Salamanca, 37007, Spain

No email / No phone

Status: Withdrawn

Research Site

London, SE1 9RT, United Kingdom

No email / No phone

Status: Withdrawn

Research Site

Orlando, Florida, 32827, United States

No email / No phone

Status: Withdrawn

Research Site

Atlanta, Georgia, 30342, United States

No email / No phone

Status: Withdrawn

Research Site

Traverse City, Michigan, 49684, United States

No email / No phone

Status: Withdrawn

Research Site

Bozeman, Montana, 59715, United States

No email / No phone

Status: Withdrawn

Research Site

Reno, Nevada, 89502, United States

No email / No phone

Status: Withdrawn

Research Site

Columbus, Ohio, 43210, United States

No email / No phone

Status: Withdrawn

Research Site

Portland, Oregon, 97213, United States

No email / No phone

Status: Withdrawn

Research Site

Knoxville, Tennessee, 37920, United States

No email / No phone

Status: Withdrawn

Research Site

Chattanooga, Tennessee, 37404, United States

No email / No phone

Status: Withdrawn

Research Site

Houston, Texas, 77030, United States

No email / No phone

Status: Withdrawn

Research Site

Huế, 530000, Vietnam

No email / No phone

Status: Withdrawn

Research Site

Vinh, 460000, Vietnam

No email / No phone

Status: Withdrawn

Research Site

Ho Chi Minh City, 700000, Vietnam

No email / No phone

Status: Withdrawn

Research Site

Koblenz, 56068, Germany

No email / No phone

Status: SUSPENDED

Research Site

Inverness, IV2 3UJ, United Kingdom

No email / No phone

Status: SUSPENDED

Research Site

Cheltenham, GL53 7AN, United Kingdom

No email / No phone

Status: SUSPENDED

Research Site

Voorhees Township, New Jersey, 08043, United States

No email / No phone

Status: SUSPENDED

Research Site

Houston, Texas, 77090, United States

No email / No phone

Status: SUSPENDED

Trial Details

Show Summary from Sponsor

More details:

Investigational Drug AI Analysis

Show for: Datopotamab deruxtecan (Dato-DXd, DS-1062)

Overview

Mechanism of action

Efficacy

Safety

Further reading

Show for: Rilvegostomig (AZD2936)

Overview

Mechanism of action

Efficacy

Safety

Further reading

TrialFetch AI Analysis

Eligibility

Show Criteria

Sites (281)

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site

Research Site